Gainers NextCure (NASDAQ:NXTC) shares rose 305.5% to $8.84 during Tuesday's pre-market session.

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-sta

Funds Advance FDA-Designated Breakthrough Therapy First-in-Class Opioid with Oral Overdose-Protectio

Gainers Seer (NASDAQ:SEER) stock moved upwards by 33.3% to $2.16 during Thursday's after-market

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-sta

~ ~ Advances First-in-Class, Breakthrough Therapy-Designated Opioid Engineered to Protect Against Or

~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~ ~ Clinical Peer-Reviewed Data Published for First

~ Patent Extends Jurisdiction and Protection Through 2042 ~ SAN DIEGO, CA / ACCESS Newswire / May 12

~ Chemical Control, Clinical Confidence: Rethinking Opioids ~ SAN DIEGO, CA / ACCESS Newswire / May

~ Advances First-in-Class Opioid with Oral Overdose-Protection ~ SAN DIEGO, CA / ACCESS Newswire / A

~Continued funding underscores investor confidence and supports advancement of abuse- and overdose-r

~ Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage

Ensysce Biosciences, Inc. (NASDAQ: ENSC - Get Free Report) was the target of a significant drop in s

~ Underscores Strategic Execution Plans, Regulatory Risk Mitigation Efforts, Pipeline Prioritization

~ Phase 1 Data Published in Journal of Opioid Management Validates First-in-Class Overdose-Limiting

Ensysce Biosciences (NASDAQ: ENSC) shares are up on Friday as the company has initiated a review of

US stocks traded lower, Dow down 600 points. Nasdaq and S&P also fell. Consumer staples up, tech

Review Includes Strategic Partnerships, Licensing and Other Corporate Transactions Focused on Advanc

~ Company leadership to highlight TAAP and MPAR programs, discuss innovation in pain therapeutics an

~ Engineered to Deliver Potent Pain Relief with Built-In Abuse Protection ~ SAN DIEGO, CA / ACCESS N

~ TAAP™ and MPAR® technologies extended across opioid products to advance safer pain treatment ~ SAN

~ New ADHD pipeline leverages TAAP™ and MPAR® technologies to improve safety for patients ~ SAN DIEG

Ensysce Biosciences, Inc. (ENSC) Shareholder/Analyst Call Prepared Remarks Transcript

PF614-301 Phase 3 Trial Enrollment Underway, Advancing Toward Market Launch FDA Aligned with ENSC Ma

New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm

  On Thursday, 369 companies hit new 52-week lows.

  On Tuesday, 647 companies set new 52-week lows.